DWIB(DANIEL WHYTE AND IVOR BURFORD) LEUKAEMIA TRUST (UK)
HOME | DWIB
Leukaemia Awareness campaigns including talks, seminars, sponsored walks, help with bone marrow drives and fund raising activities.
1127494
IČO
2009
Založeno
SW9 9BA
Adresa
dwib.org
Web
Podobné organizace
CHRONIC MYELOID LEUKAEMIA SUPPORT GROUP |
|
AFRICAN CARIBBEAN LEUKAEMIA TRUST |
|
Leukaemia UK Organisation Ltd |
|
Leukaemia UK |
|
EMMA'S AIM |
Novinky
Poslední komentáře
So inspired by the amazing work the DWIB Leukaemia Trust is doing to raise awareness and support for those affected by leukaemia! Let's all get involved and help spread the word! 💖 #LeukaemiaAwarenessdetail |
|
Kudos to Dr. Rosanna Jackson for highlighting the advancements in kinder treatments for children! Every step forward is a step towards hope. 🌈✨ #ChildhoodLeukaemia #DWIBLeukaemiaTrustdetail |
Poslední diskuze
- What impact do you think recent advancements in leukaemia treatments will have on long-term survival rates for children diagnosed with the disease?Odpovědí: 3, Naposledy před 1 den detail |
|
- How can community awareness initiatives, like those during Blood Cancer Awareness Month, be improved to effectively educate the public about leukaemia symptoms?Odpovědí: 3, Naposledy před 1 den detail |
V okolí
4.5
Reviews
SW9 9BA
Místo
O společnosti
- G21, Z99, E20 -
HOME ABOUT US NEWS WHAT IS LEUKAEMIA. AFILIATES PARTNERS CONTACT More Daniel Whyte Ivor Burford Leukaemia Trust In this guest blog post Dr Rosanna Jackson discusses what scientists are doing to make treatment kinder for children with acute lymphoblastic leukaemia ALL. The FDA has approved a new cancer drug from AstraZeneca the first medicine to treat a rare and lifethreatening form of leukaemia to hit the market for 20 years. Clinicalstage biopharmaceutical company ASLAN Pharmaceuticals has been granted orphan drug designation ODD for its treatment for acute myeloid leukaemia AML ASLAN003 by the US Food and Drug Administration FDA.
Neznámá kategorie Nemocnice a zařízení primární zdravotní péče
23 Vacancy
More Detail
